Prevention and treatment of chemotherapy- and radiotherapy-induced oral mucositis:: a review

被引:97
作者
Plevová, P [1 ]
机构
[1] Univ Ostrava, Univ Hosp Ostrava, Dept Radiotherapy, CZ-70852 Ostrava, Czech Republic
关键词
stomatitis prevention; stomatitis control; antineoplastic agents; chemically induced; radiotherapy-adverse effects;
D O I
10.1016/S1368-8375(99)00033-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oral mucositis is a distressing toxic effect of systemic chemotherapy with many commonly utilized drugs and of head and neck irradiation in patients with cancer. The agents and methods that have been used and studied in chemotherapy- and radiotherapy-induced oral mucositis, their mechanisms of action, and the current knowledge of their efficiency to reduce the incidence, severity or shorten the duration of oral mucositis are reviewed in this article. Oral cooling is a cheap and available method to lower the severity of bolus 5-fluorouracil-induced oral mucositis. However, more effective methods are needed. Results of studies with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor are promising. Lasers are partly beneficial, but equipment-demanding. Modification of the chemotherapy regimen resulting in shortening of the exposition time to chemotherapy agents or chronomodulation of chemotherapy has been shown to lower mucosal toxicity of some regimens. Results of animal studies with locally applied transforming growth factor beta 3 and interleukin-11 are also promising. Based on the findings of the role of the inflammatory cascade in the response of normal tissues to chemotherapy and radiotherapy, anti-inflammatory drugs might be beneficial. At the present time, no agent has been shown to be uniformly efficacious and can be accepted as standard therapy of chemotherapy- and radiotherapy-induced oral mucositis. Further intensive research is needed. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:453 / 470
页数:18
相关论文
共 237 条
  • [1] ABDELAAL AS, 1989, LANCET, V1, P97
  • [2] HIGH-DOSE METHOTREXATE - A CRITICAL REAPPRAISAL
    ACKLAND, SP
    SCHILSKY, RL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (12) : 2017 - 2031
  • [3] AHMED T, 1993, BONE MARROW TRANSPL, V12, P131
  • [4] Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: Relation to oral mucositis
    Albertioni, F
    Rask, C
    Schroeder, H
    Peterson, C
    [J]. ANTI-CANCER DRUGS, 1997, 8 (02) : 119 - 124
  • [5] SYMPTOMATIC ACUTE MUCOSITIS CAN BE MINIMIZED OR PROPHYLAXED BY THE COMBINATION OF SUCRALFATE AND FLUCONAZOLE
    ALLISON, RR
    VONGTAMA, V
    VAUGHAN, J
    SHIN, KH
    [J]. CANCER INVESTIGATION, 1995, 13 (01) : 16 - 22
  • [6] Anderson PM, 1998, CANCER, V83, P1433, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1433::AID-CNCR22>3.0.CO
  • [7] 2-4
  • [8] GM-CSF AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION - ACCELERATED RECOVERY OF NEUTROPHILS, MONOCYTES AND LYMPHOCYTES
    ATKINSON, K
    BIGGS, JC
    DOWNS, K
    JUTTNER, C
    BRADSTOCK, K
    LOWENTHAL, RM
    DALE, B
    SZER, J
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1991, 21 (05): : 686 - 692
  • [9] ATTAL M, 1993, BLOOD, V82, P732
  • [10] BARASCH A, 1995, CANCER, V76, P2550, DOI 10.1002/1097-0142(19951215)76:12<2550::AID-CNCR2820761222>3.0.CO